Do analysts recommend ACB or KPTI?

Karyopharm Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 483.76%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Karyopharm Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57

Does the media favor ACB or KPTI?

In the previous week, Aurora Cannabis had 7 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 17 mentions for Aurora Cannabis and 10 mentions for Karyopharm Therapeutics. Aurora Cannabis' average media sentiment score of 0.68 beat Karyopharm Therapeutics' score of -0.51 indicating that Aurora Cannabis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 3 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer KPTI or LENZ?

In the previous week, Karyopharm Therapeutics had 8 more articles in the media than LENZ Therapeutics. MarketBeat recorded 10 mentions for Karyopharm Therapeutics and 2 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.00 beat Karyopharm Therapeutics' score of -0.51 indicating that LENZ Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative LENZ Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is KPTI or LFCR more profitable?

Lifecore Biomedical has a net margin of -29.93% compared to Karyopharm Therapeutics' net margin of -129.02%. Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics -129.02% N/A -120.29% Lifecore Biomedical -29.93% N/A -16.16%

Does the media refer more to KPTI or LFCR?

In the previous week, Karyopharm Therapeutics and Karyopharm Therapeutics both had 10 articles in the media. Lifecore Biomedical's average media sentiment score of 0.35 beat Karyopharm Therapeutics' score of -0.51 indicating that Lifecore Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Lifecore Biomedical 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MENS or KPTI?

Karyopharm Therapeutics has a consensus target price of $11.50, indicating a potential upside of 483.76%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Karyopharm Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57

Which has preferable valuation & earnings, MENS or KPTI?

Jyong Biotech has higher earnings, but lower revenue than Karyopharm Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Karyopharm Therapeutics $146.07M 0.31 -$196.04M -$15.09 N/A

Is MENS or KPTI more profitable?

Jyong Biotech has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Karyopharm Therapeutics -129.02% N/A -120.29%

Does the media favor KPTI or CRDL?

In the previous week, Karyopharm Therapeutics had 7 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 10 mentions for Karyopharm Therapeutics and 3 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.00 beat Karyopharm Therapeutics' score of -0.51 indicating that Cardiol Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Karyopharm Therapeutics (KPTI) Competitors

$1.97 -0.15 (-7.08%)

As of 01:40 PM Eastern

Compare

KPTI vs. ACB, LENZ, LFCR, MENS, and CRDL

Should you buy Karyopharm Therapeutics stock or one of its competitors? MarketBeat compares Karyopharm Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Karyopharm Therapeutics include Aurora Cannabis (ACB), LENZ Therapeutics (LENZ), Lifecore Biomedical (LFCR), Jyong Biotech (MENS), and Cardiol Therapeutics (CRDL). These companies are all part of the "pharmaceuticals" industry.

How does Karyopharm Therapeutics compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Aurora Cannabis had 7 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 17 mentions for Aurora Cannabis and 10 mentions for Karyopharm Therapeutics. Aurora Cannabis' average media sentiment score of 0.68 beat Karyopharm Therapeutics' score of -0.51 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurora Cannabis	3 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aurora Cannabis has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

Karyopharm Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 483.76%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Aurora Cannabis has higher revenue and earnings than Karyopharm Therapeutics. Aurora Cannabis is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$247.82M	0.72	-$88.13M	-$1.41	N/A
Karyopharm Therapeutics	$146.07M	0.31	-$196.04M	-$15.09	N/A

Aurora Cannabis has a net margin of -32.26% compared to Karyopharm Therapeutics' net margin of -129.02%. Aurora Cannabis' return on equity of 4.37% beat Karyopharm Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-32.26%	4.37%	3.45%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Summary

Aurora Cannabis beats Karyopharm Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to LENZ Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Karyopharm Therapeutics currently has a consensus target price of $11.50, indicating a potential upside of 483.76%. LENZ Therapeutics has a consensus target price of $29.80, indicating a potential upside of 454.83%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Karyopharm Therapeutics is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
LENZ Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Karyopharm Therapeutics had 8 more articles in the media than LENZ Therapeutics. MarketBeat recorded 10 mentions for Karyopharm Therapeutics and 2 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.00 beat Karyopharm Therapeutics' score of -0.51 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
LENZ Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LENZ Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.31	-$196.04M	-$15.09	N/A
LENZ Therapeutics	$19.09M	8.82	-$82.13M	-$3.60	N/A

Karyopharm Therapeutics has a net margin of -129.02% compared to LENZ Therapeutics' net margin of -519.30%. Karyopharm Therapeutics' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Karyopharm Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Summary

Karyopharm Therapeutics beats LENZ Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Lifecore Biomedical?

Karyopharm Therapeutics (NASDAQ:KPTI) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Karyopharm Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Karyopharm Therapeutics and Karyopharm Therapeutics both had 10 articles in the media. Lifecore Biomedical's average media sentiment score of 0.35 beat Karyopharm Therapeutics' score of -0.51 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Lifecore Biomedical	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lifecore Biomedical has a net margin of -29.93% compared to Karyopharm Therapeutics' net margin of -129.02%.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Karyopharm Therapeutics presently has a consensus target price of $11.50, suggesting a potential upside of 483.76%. Lifecore Biomedical has a consensus target price of $6.50, suggesting a potential upside of 35.14%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Karyopharm Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lifecore Biomedical has lower revenue, but higher earnings than Karyopharm Therapeutics. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.31	-$196.04M	-$15.09	N/A
Lifecore Biomedical	$128.87M	1.41	-$40.50M	-$1.07	N/A

Summary

Lifecore Biomedical beats Karyopharm Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Karyopharm Therapeutics has a consensus target price of $11.50, indicating a potential upside of 483.76%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Jyong Biotech has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Jyong Biotech has higher earnings, but lower revenue than Karyopharm Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Karyopharm Therapeutics	$146.07M	0.31	-$196.04M	-$15.09	N/A

In the previous week, Karyopharm Therapeutics had 10 more articles in the media than Jyong Biotech. MarketBeat recorded 10 mentions for Karyopharm Therapeutics and 0 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 0.00 beat Karyopharm Therapeutics' score of -0.51 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Jyong Biotech	Neutral
Karyopharm Therapeutics	Negative

Jyong Biotech has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Karyopharm Therapeutics beats Jyong Biotech on 8 of the 13 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Cardiol Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Karyopharm Therapeutics currently has a consensus price target of $11.50, indicating a potential upside of 483.76%. Cardiol Therapeutics has a consensus price target of $8.50, indicating a potential upside of 480.20%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cardiol Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.31	-$196.04M	-$15.09	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

In the previous week, Karyopharm Therapeutics had 7 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 10 mentions for Karyopharm Therapeutics and 3 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.00 beat Karyopharm Therapeutics' score of -0.51 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Karyopharm Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

Cardiol Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Summary

Karyopharm Therapeutics beats Cardiol Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Karyopharm Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPTI vs. The Competition

Export

Metric	Karyopharm Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$44.30M	$11.92B	$7.04B	$12.92B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-0.13	788.54	269.97	24.82
Price / Sales	0.31	967.38	650.66	108.09
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	-0.12	10.33	11.26	6.44
Net Income	-$196.04M	$2.77B	$3.45B	$347.27M
7 Day Performance	N/A	1.99%	3.62%	2.55%
1 Month Performance	-80.95%	-1.56%	-0.56%	-1.02%
1 Year Performance	-50.00%	191.17%	77.38%	23.33%

Karyopharm Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPTI Karyopharm Therapeutics	2.2131 of 5 stars	$1.97 -7.1%	$11.50 +483.8%	-46.2%	$44.30M	$146.07M	N/A	380
ACB Aurora Cannabis	1.1432 of 5 stars	$2.83 +1.4%	N/A	-33.3%	$172.82M	$247.82M	N/A	1,028	Analyst Upgrade
LENZ LENZ Therapeutics	2.157 of 5 stars	$4.99 -5.8%	$29.80 +497.2%	-84.5%	$166.18M	$19.09M	N/A	110	Positive News
LFCR Lifecore Biomedical	1.7416 of 5 stars	$4.39 -0.7%	$6.50 +48.1%	-30.8%	$165.79M	$128.87M	N/A	690	Earnings Report
MENS Jyong Biotech	N/A	$2.00 -7.0%	N/A	-95.5%	$163.46M	N/A	N/A	31

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPTI) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. ACB, LENZ, LFCR, MENS, and CRDL

How does Karyopharm Therapeutics compare to Aurora Cannabis?

Summary

How does Karyopharm Therapeutics compare to LENZ Therapeutics?

Summary

How does Karyopharm Therapeutics compare to Lifecore Biomedical?

Summary

How does Karyopharm Therapeutics compare to Jyong Biotech?

Summary

How does Karyopharm Therapeutics compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. ACB, LENZ, LFCR, MENS, and CRDL

How does Karyopharm Therapeutics compare to Aurora Cannabis?

Does the media favor ACB or KPTI?

Do insiders and institutionals have more ownership in ACB or KPTI?

Which has more volatility and risk, ACB or KPTI?

Do analysts recommend ACB or KPTI?

Which has better earnings and valuation, ACB or KPTI?

Is ACB or KPTI more profitable?

Summary

How does Karyopharm Therapeutics compare to LENZ Therapeutics?

Do analysts recommend KPTI or LENZ?

Does the media prefer KPTI or LENZ?

Which has better valuation & earnings, KPTI or LENZ?

Is KPTI or LENZ more profitable?

Do insiders and institutionals have more ownership in KPTI or LENZ?

Which has more risk & volatility, KPTI or LENZ?

Summary

How does Karyopharm Therapeutics compare to Lifecore Biomedical?

Which has more risk and volatility, KPTI or LFCR?

Do insiders & institutionals hold more shares of KPTI or LFCR?

Does the media refer more to KPTI or LFCR?

Is KPTI or LFCR more profitable?

Do analysts recommend KPTI or LFCR?

Which has better valuation & earnings, KPTI or LFCR?

Summary

How does Karyopharm Therapeutics compare to Jyong Biotech?

Do analysts rate MENS or KPTI?

Is MENS or KPTI more profitable?

Which has preferable valuation & earnings, MENS or KPTI?

Does the media prefer MENS or KPTI?

Which has more volatility and risk, MENS or KPTI?

Do insiders & institutionals believe in MENS or KPTI?

Summary

How does Karyopharm Therapeutics compare to Cardiol Therapeutics?

Do analysts recommend KPTI or CRDL?

Which has higher valuation & earnings, KPTI or CRDL?

Does the media favor KPTI or CRDL?

Do insiders & institutionals believe in KPTI or CRDL?

Which has more volatility and risk, KPTI or CRDL?

Is KPTI or CRDL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools